1. Introduction {#s0005}
===============

Osteoporosis is prevalent in the Asia-Pacific region, and the prevalence and burden of osteoporosis-related fractures are expected to increase over the coming decades as the populations of Asia-Pacific countries become older ([@bb0095]). To reduce the risk of fracture, national and international guidelines recommend pharmacologic treatment for patients with an osteoporotic fracture, with evidence of low bone mineral density (BMD; generally corresponding to a T-score ≤ − 2.5), or with a combination of low BMD and increased fracture risk ([@bb0115], [@bb0090], [@bb0135], [@bb0055], [@bb0140]).

Gastrointestinal (GI) events are also prevalent in Asia-Pacific countries ([@bb0010], [@bb0030], [@bb0130]), and such events have been shown to be exacerbated by treatment for osteoporosis in Asian populations ([@bb0110], [@bb0125]). Studies from the United States have found that a history of GI events can reduce the likelihood of initiating anti-osteoporosis treatment ([@bb0100], [@bb0015]). However, little is known about the influence of GI events on treatment practices in the Asia-Pacific region.

Osteoporosis treatment guidelines from Australia ([@bb0135]) note the potential side effects of bisphosphonate use, but other than this, there is little guidance available for Asia-Pacific physicians regarding patients with a history of GI events. The Medication Use Patterns, Treatment Satisfaction, and Inadequate Control of Osteoporosis Study in the Asia-Pacific Region (MUSIC OS-AP) ([@bb0105]) included a physician questionnaire that allowed us to assess the relationship between patients\' GI history and physicians\' prescribing practices. This article describes Asia-Pacific physicians\' approaches to the management of osteoporosis patients with GI events and identifies the physician-reported factors associated with the decision of whether or not to treat osteoporosis with pharmacotherapy in clinical practice.

2. Methods {#s0010}
==========

2.1. Study design {#s0015}
-----------------

The 3-component design of MUSIC OS-AP has been described in a previous publication ([@bb0105]). In the component reported here---the physician questionnaire---physicians\' management of female osteoporosis patients was examined cross-sectionally, with an emphasis on the role of GI events in treatment decisions.

2.2. Study sample {#s0020}
-----------------

Prior to the commencement of the prospective component of the MUSIC OS-AP study, each investigator completed a short physician questionnaire. Physicians from 5 Asia-Pacific countries (Australia, India, Korea, New Zealand, and Taiwan) were selected for participation via assessment of their experience in conducting clinical research, interest in participation, and ability to dedicate time and resources to the study. All study sites completed ethics reviews according to their local ethics board requirements.

2.3. Study outcomes {#s0025}
-------------------

The questionnaire collected information about the physician\'s standard practices for treatment of patients with osteoporosis. Physicians were asked how often they witnessed GI events (e.g., heartburn, upset stomach, nausea, or pain) and how often GI sensitivity impacted their decision to prescribe osteoporosis treatment and their choice of medication. Treatment strategies for patients who had pre-existing GI events or developed GI events after starting osteoporosis therapy were queried (e.g., prescribe a gastroprotective agent, recommend a drug holiday, or switch to another medication). The text of the questions is provided as a footnote to each table and figure.

2.4. Statistical analysis {#s0030}
-------------------------

The analyses were descriptive in nature, and no statistical comparisons were performed. Continuous variables are reported as mean percentage values, or as medians and ranges (minimum and maximum values). For survey questions with categorical responses (e.g., always, often, sometimes, rarely, and never), the percentage of physicians responding in each category is reported.

3. Results {#s0035}
==========

3.1. Study participants {#s0040}
-----------------------

A total of 59 physicians completed the questionnaire: 20 from Australia/New Zealand, 15 from India, 15 from Korea, and 9 from Taiwan ([Table 1](#t0005){ref-type="table"}). Sixteen worked at primary care clinics and 43 at specialty centers.Table 1Number of physicians by country.Table 1CountryN (%) physiciansAustralia/New Zealand20 (33.9)India15 (25.4)Korea15 (25.4)Taiwan9 (15.3)

3.2. Treatment and non-treatment of osteoporosis {#s0045}
------------------------------------------------

When choosing a medication for treatment-naïve patients, renal insufficiency, menopausal status, and age were always a consideration for 54%, 49%, and 41% of physicians, respectively ([Fig. 1](#f0005){ref-type="fig"}). GI sensitivity was often or always a consideration for a combined 79% of physicians ([Fig. 1](#f0005){ref-type="fig"}). The most frequently prescribed or recommended treatments ([Table 2](#t0010){ref-type="table"}) were vitamin D (84% of patients), calcium (82% of patients), and oral bisphosphonates (59% of patients).Fig. 1Factors that impact osteoporosis therapy among treatment-naïve patients.^aa^Survey question: when choosing an osteoporosis medication for treatment-naïve postmenopausal women aged 50 years or older, how often do the following factors impact your choice?Renal insufficiency was defined as creatinine clearance \< 35 mL/min.Fig. 1Table 2Percentage of patients to whom physicians prescribe or recommend one or more of the listed osteoporosis therapies.[a](#tf0005){ref-type="table-fn"}Table 2TherapyMean percentage of patientsVitamin D84Calcium82Oral bisphosphonate therapy[b](#tf0010){ref-type="table-fn"}59Calcitriol27Denosumab19Injectable bisphosphonate therapy[c](#tf0015){ref-type="table-fn"}17Selective estrogen receptor modulators[d](#tf0020){ref-type="table-fn"}12Calcitonin or elcatonin10Parathyroid hormone or teriparatide8Strontium8Estrogen or hormone therapy8[^2][^3][^4][^5]

Among physicians not prescribing pharmacologic treatment ([Table 3](#t0015){ref-type="table"}), the most common reason for not treating osteoporosis was the patient\'s unwillingness to take the medication (42% of the time), followed by abnormal renal function (21%). GI sensitivity was a reason 18% of the time ([Table 3](#t0015){ref-type="table"}).Table 3Reasons for non-treatment.[a](#tf0025){ref-type="table-fn"}Table 3Mean percentage of non-prescriptionsPatient is unwilling to take for medical or other reasons42Patient has abnormal renal function (e.g. creatinine clearance \< 35 mL/min)21Gastrointestinal sensitivity18Despite low BMD, absolute fracture risk is low17Physician is unwilling to prescribe for medical or other reasons11[^6]

3.3. Physicians\' observations regarding GI events {#s0050}
--------------------------------------------------

The GI events most frequently observed by physicians among their treated patients were upset stomach/indigestion (observed sometimes or often by 88% of physicians) and heartburn/acid reflux (observed sometimes or often by 85% of physicians; [Fig. 2](#f0010){ref-type="fig"}). Bloating was observed sometimes or often by 57% of physicians ([Fig. 2](#f0010){ref-type="fig"}). Physicians reported that a median (range) of 20% (0--75%) of patients had experienced upper GI events and 10% (0--40%) had experienced lower GI events before starting pharmacologic treatment, whereas they estimated that 10% (1--50%) of patients experienced a new GI event after starting treatment. New GI events were reported to commence within the first month of treatment by 75% of physicians and within the first 3 months of starting treatment by 98% of physicians.Fig. 2Frequency of gastrointestinal events among treated patients.^aa^Survey question: how often do you see the following gastrointestinal events in postmenopausal women aged 50 years or older who are receiving osteoporosis treatment?Fig. 2

3.4. Treatment strategies in patients with GI events {#s0055}
----------------------------------------------------

For patients with pre-existing GI conditions, physicians most frequently ranked use of non-oral osteoporosis medication as the first treatment strategy (47% of physicians), followed by co-prescription with a proton pump inhibitor or other gastro-protective agent (31%) and modification of the frequency or dosing of the drug (17%; [Fig. 3](#f0015){ref-type="fig"}a). For patients with GI symptoms developing after starting pharmacologic treatment, the most frequently first-ranked treatment strategy was to check if the patient was taking their osteoporosis medication correctly as prescribed (64% of physicians), followed by temporary discontinuation of the medication (i.e., a drug holiday) until GI events have resolved (31%) and co-prescription with a proton pump inhibitor or other gastroprotective agent (24%; [Fig. 3](#f0015){ref-type="fig"}b).Fig. 3Physician treatment approaches for (a) patients with pre-existing GI conditions and (b) patients developing GI symptoms after starting treatment.^a^GI, gastrointestinal; OP, osteoporosis^a^Panel (a) Survey question: If one of your female patients is a candidate for osteoporosis medication(s) and has pre-existing GI events, please rank (from 1, 2, 3...) the normal sequence of treatment options you would select. Panel (b) Survey question: If one of your female patients taking osteoporosis medication(s) develops a GI event, please rank (from 1, 2, 3...) the normal sequence of treatment options you would select.Fig. 3

4. Discussion {#s0060}
=============

This analysis of data from the physician questionnaire of MUSIC OS-AP provides novel insights into the role of GI events in the typical prescribing practices of a sample of physicians for osteoporotic women in the Asia-Pacific region. GI events, although not the most frequently considered factor, did appear to affect physicians\' decision to treat and the types of treatment prescribed. Physicians reported using different treatment strategies depending on the patient\'s history of GI events. Similar effects of GI events on osteoporosis treatment have been reported in US studies, where a GI diagnosis was a common reason (28% of untreated patients) for not initiating bisphosphonate therapy in a cross-sectional study of osteoporosis patients aged 25 years and older ([@bb0050]) and osteoporosis patients aged 50 years and older included in an analysis of nursing home residents with a history of GI events (esophagitis, peptic ulcer disease, or dysphagia) were less likely to receive osteoporosis therapy than patients without a history of GI events ([@bb0015]).

Physicians in the Asia-Pacific region showed a preference for non-prescription therapies, such as vitamin D and calcium. However, they estimated that up to 59% of their patients were receiving prescription pharmacotherapies such as bisphosphonates and denosumab. This treatment rate is consistent with published treatment rates of up to \~ 63% in Korea ([@bb0060], [@bb0075], [@bb0070]) and 29% in Australia ([@bb0025]).

For physicians in MUSIC OS-AP, the primary considerations when deciding to treat osteoporosis patients were renal function, menopausal status, and age. These factors differed somewhat from a recent survey of US physicians, which showed that, when deciding whether to prescribe bisphosphonates, known risk factors for osteoporotic fracture, such as fracture history, glucocorticoid use, and BMD test scores, were the major considerations for physicians ([@bb0035]). However, a previous survey of 100 physician members the Korean Society for Bone and Mineral Research (KSBMR) found that 99% used BMD measurements when making treatment decisions ([@bb0040]), and a survey of 114 Australian general practitioners found that rates of both prescription and non-prescription treatment were higher in patients with a history of osteoporotic fracture ([@bb0045]), indicating that doctors in the Asia-Pacific region do consider fracture risk factors when treating their patients. MUSIC OS-AP differed from these previous surveys by focusing specifically on the role of GI events in prescribing decisions.

According to physicians in MUSIC OS-AP, the most common reason for not treating osteoporosis was the patient\'s unwillingness to take the medication. US patient surveys have shown that experience of side effects and fear of side effects are associated with patient unwillingness to initiate osteoporosis therapies ([@bb0085], [@bb0145]). Consistent with the supposition that such side effects would include GI events, physicians in MUSIC OS-AP estimated that GI sensitivity was the reason for non-treatment in about one fifth of cases. Similarly, Australian physicians surveyed regarding the management of minimal trauma hip fracture patients reported that gastroesophageal reflux would be a contraindication for bisphosphonate treatment ([@bb0080]).

In the KSBMR survey described above, physicians identified a lack of patient awareness (50%), restrictions by health insurance (47%), and the costs of medication (28%) as the biggest barriers to osteoporosis treatment ([@bb0040]). Similarly, a 2010 survey of 247 physician attendees of the first Asian regional osteoporosis meeting of the International Osteoporosis Foundation identified lack of awareness among physicians and patients as the most important barrier to osteoporosis care ([@bb0065]). Awareness was not assessed in MUSIC OS-AP, but, consistent with the KSBMR survey, formulary access (access to certain, specified medications) and medication costs were found to be often or always a consideration for 59% and 38% of physicians, respectively, in the current study.

Physicians in MUSIC OS-AP estimated that 20% and 10% of patients had experienced upper and lower GI events, respectively, before starting pharmacologic treatment. These results are consistent with the findings from the2005--2008 Nutrition and Health Survey in Taiwan, in which 33.2% of adult women had functional GI disorders ([@bb0010]) and with other population-based studies from Asia and Australia that report GI event rates around 10--20% ([@bb0030], [@bb0130]).

Almost half (47%) of physicians in MUSIC OS-AP reported that, for patients with pre-existing GI conditions, prescription of non-oral osteoporosis medication is the first treatment strategy. Among US physicians, although injectable bisphosphonate formulations are gaining popularity, oral bisphosphonates still appear to be the preferred type of prescribed treatment ([@bb0035]). Another commonly used strategy in MUSIC OS-AP was modification of the frequency or dosing of the drug, reported as a first-choice strategy by 17% of physicians. This is consistent with US studies showing that less frequent dosing decreases the occurrence of gastrointestinal symptoms in patients taking bisphosphonates ([@bb0005], [@bb0020]) and with a study from Korea reporting better composite treatment satisfaction scores in monthly versus weekly bisphosphonate users ([@bb0120]). For patients with GI symptoms developing after starting pharmacologic treatment, 31% of physicians in the current study reported temporary discontinuation of the medication (i.e., a drug holiday) until GI events have resolved as their preferred strategy. This agrees with the practices of US physicians, most of whom reported incorporating a drug holiday into their prescribing regimen in a recent survey ([@bb0035]).

One limitation of the physician questionnaire of MUSIC OS-AP was its small sample size, which did not allow the assessment of differences between physicians from different countries and between physicians of various specialties. Also, as noted above, the questions were focused on the role of GI events in treatment practices, and thus did not address other topics commonly reported in other physician surveys (e.g., whether risk factors for fracture such as fracture history or BMD influenced treatment decisions). However, this focus allowed MUSIC OS-AP to provide new information on how physicians deal with GI events when managing their osteoporosis patients. Finally, the cross-sectional survey design is limited by the accuracy of physician recall.

5. Conclusion {#s0065}
=============

In conclusion, the results of this study show that GI events influence the prescribing practices of physicians in the Asia-Pacific region and sometimes result in non-treatment of women with osteoporosis.
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[^1]: Recently deceased.

[^2]: Survey question: think about the last 20 postmenopausal women aged 50 years or older you diagnosed with osteoporosis. In approximately what percentage of these women did you prescribe or recommend the following bone-related treatments?

[^3]: Risedronate, alendronate, ibandronate, and etidronate.

[^4]: Pamidronate, zoledronic acid, and ibandronate.

[^5]: Raloxifene and bazedoxifene.

[^6]: Survey question: when you do not prescribe a pharmacological treatment (including calcium, vitamin D, estrogen and HRT) for a treatment-naïve postmenopausal woman aged 50 years or older with osteoporosis, how often (in percentage terms) would this be due to the following reasons?
